Association of polycystic ovary syndrome with cardiovascular risk factors

References

• Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic Ovary Syndrome. Oxford, England: Blackwell Scientific; 1992. pp 377–384.
   Google Scholar
• Bulun SE, Adashi EY. The physiology and pathology of the female reproductive axis. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams Text Book of Endocrinology. Philadelphia, PA: Saunders; 2003. pp 627–630.
   Google Scholar
• Swanson M, Sauebrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 1981;9:219–222.
   PubMed Web of Science ®Google Scholar
• Loucks TL, Talbott EO, Mc Hugh KP, Keelan M, Berga SL, Guzick DS. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fertil Steril 2000;74:547–552.
   PubMed Web of Science ®Google Scholar
• Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Morris DV, Prince J, Jacobs JS. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375–1379.
   PubMed Web of Science ®Google Scholar
• Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005;83:1343–1346.
   PubMed Web of Science ®Google Scholar
• Kousta E, White DM, Cela E, McCarthy MI, Franks S. The prevalence of polycystic ovaries in women with infertility. Hum Reprod 1999;14:2720–2723.
   PubMed Web of Science ®Google Scholar
• Eden JA, Place J, Carter GD, Alaghband-Zadeh J, Pawson M. Is the polycystic ovary a cause of infertility in the ovulatory women? Clin Endocrinol (Oxf) 1989;30:77–82.
   PubMed Web of Science ®Google Scholar
• Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycysic ovary syndrome? Best Pract Res Clin Obstet Gynecol 2004;18:671–683.
   PubMed Web of Science ®Google Scholar
• Marshall K. Polycystic ovary syndrome: clinical considerations. Altern Med Rev 2001;6:272–292.
   PubMedGoogle Scholar
• Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606–2609.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin through pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46–52.
   PubMed Web of Science ®Google Scholar
• Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endo Metab 1970;30:435–442.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome. J Clin Invest 1989;83:23–29.
   PubMed Web of Science ®Google Scholar
• Poretsky L, Piper B. Insulin resistance, hypersecretion of LH, and a dual defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 1994;84:613–621.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322–353.
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861.
   PubMed Web of Science ®Google Scholar
• Utiger RD. Insulin and polycystic ovary syndrome. N Engl J Med 1996;335:657–658.
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93–99.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Wood C. The current status of polycystic ovary syndrome. Aust NZ J Obstet Gynecol 2001;41:65–68.
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158–1165.
   PubMed Web of Science ®Google Scholar
• Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996;81:4103–4107.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Bellows AB, Gingrich MB, Hu Y, Evans WS, Marshall JC, Veldhuis JD. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2004;286:E902–E908.
   PubMed Web of Science ®Google Scholar
• DeUgrate CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454–1460.
   PubMed Web of Science ®Google Scholar
• Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol Endocrinol Metab 1993;264:197–202.
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904–910.
   PubMed Web of Science ®Google Scholar
• Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Fertil Steril 1992;37:119–125.
   Google Scholar
• Kravariri M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088–5095.
   PubMed Web of Science ®Google Scholar
• Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302–312.
   PubMed Web of Science ®Google Scholar
• Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. Fertil Steril 2002;87:2013–2017.
   Google Scholar
• Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes Care 1997;20:1087–1092.
   PubMed Web of Science ®Google Scholar
• Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Alan S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357–1363.
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.
   PubMed Web of Science ®Google Scholar
• Essah PA, Nestler JE. Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S18–S19.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237–4245.
   PubMed Web of Science ®Google Scholar
• Shroff R, Syrop CH, Davis W, Voorhis BJV, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertile Steril 2007:1–7 (in press).
   Web of Science ®Google Scholar
• Mattson LA, Cullberg G, Hamberger L, Samsioe G, Silfverstolpe G. Lipid metabolism in women with polycystic ovary syndrome: possible implications for increased risk of coronary heart disease. Fertile Steril 1984;42:579–584.
   PubMed Web of Science ®Google Scholar
• Wild RA. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995;98:27S–32S.
   PubMed Web of Science ®Google Scholar
• Talbott E, Clerici A, Berge SL, Kuller L, Guzick D, Detre K, Daniels T, Enberg RA. Adverse lipid and coronary heart disease risk profiles in young women with PCOS: results of a case control study. J Clin Epidemiology 1998;51:415–422.
   PubMed Web of Science ®Google Scholar
• Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 1999;72:990–995.
   PubMed Web of Science ®Google Scholar
• Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN. Altered composition of high density lipoproteins in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389–3393.
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821–826.
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003;80: No. 2.
   PubMed Web of Science ®Google Scholar
• Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73:150–156.
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome. Fertil Steril 1993;76:1295–1300.
   Google Scholar
• Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 α activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–4079.
   PubMed Web of Science ®Google Scholar
• Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex-hormone binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988;67:460–464.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex-hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89.
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M. Insulin infusion amplifies 17 α- hydroxycorticoid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent impairment of 17, 20-lyase activity. J Clin Endocrinol Metab 1996;81:881–886.
   PubMed Web of Science ®Google Scholar
• Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113–116.
   PubMed Web of Science ®Google Scholar
• Chang RJ, Nakamura RM, Judd HL, Kaplan SL. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356–359.
   PubMed Web of Science ®Google Scholar
• Jialal I, Naiker P, Reddi K, Moodley J, Joubert SM. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1987;64:1066–1069.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Mahabeer S, Jialal I, Norman RJ, Naidoo C, Reddi K, Joubert SM. Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease. Hormone Metab Res 1989;21:502–506.
   PubMed Web of Science ®Google Scholar
• Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, Johnston DJ, Franks S. The relationship of insulin sensitivity to menstrual pattern in women hyperandrogenism and polycystic ovaries. Clin Endocrinol 1993;39:351–355.
   PubMed Web of Science ®Google Scholar
• Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome: comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682–4688.
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Spaczynski RZ, Pelesz M, Pawelczyk L. Incidence of LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Annales Academiae Medicae Bialostocensis 2003;48:131–134.
   Google Scholar
• Christian RC, Dumesic DA, Behrenbeck T, Oberg A, Sheedy PF, Fitzpatrick L. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562–2568.
   PubMed Web of Science ®Google Scholar